Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Tickers AXSM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.